Measles Virus-Infected Stem Cells for Ovarian Cancer

Recruiting in Palo Alto (17 mi)

Evanthia Galanis, M.D. - Doctors and ...

Overseen byEvanthia Galanis

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.

Eligibility Criteria

This trial is for patients with recurrent ovarian, primary peritoneal or fallopian tube cancer who have previously been treated with platinum and taxanes. Participants must have adequate organ function, an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and no history of certain other conditions like severe allergies to measles vaccine or immunodeficiency.

Inclusion Criteria

Your white blood cell count is at least 1500 cells per microliter.

My ovarian, peritoneal, or fallopian tube cancer has returned or worsened after treatment with platinum and taxanes.

Your AST blood test result is not more than twice the upper limit of normal. This test must have been done within 7 days before you join the study.

+15 more

Exclusion Criteria

I have not had an active infection in the last 5 days.

I need blood transfusions or products to manage my condition.

I am not currently receiving any experimental treatments.

+22 more

Participant Groups

The study is testing the safety and effectiveness of MV-NIS infected mesenchymal stem cells in treating recurrent cancers mentioned above. It's looking for the best dose that can carry tumor-killing substances directly to cancer cells without causing too many side effects.

1Treatment groups

Experimental Treatment

Group I: Treatment (MV-NIS infected mesenchymal stem cells)Experimental Treatment10 Interventions

Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA prior to registration and blood sample collection, chest X-ray, SPECT/CT, CT or MRI throughout the study.